SARS-CoV-2 Antibodies

Detection and inhibition of target proteins

Sequence and structure of the coronavirus SARS-CoV-2 are well understood and potential targets for vaccines and therapeutics have been identified. Specific recombinant antibodies against these target proteins are an important tool for further research into the mode of action of the virus and the diverse clinical picture of COVID-19 as well as for drug development. With the help of our partners, we are able to offer you a wide range of specific antibodies and antibody fragments against various relevant SARS-CoV-2 antigens.

The nucleocapsid protein (N) is the most detectable protein in corona viruses. It is very immunogenic and highly conserved. The spike protein (S) on the surface of the virus envelope is essential for virus entry and an important target for antibodies and vaccines. (Walls et al., Cell 2020)

A key enzyme is nsp12 polymerase, with two cofactors essential for nucleotide polymerization, nsp7 and nsp8. (Kirchdoerfer et al., Nature 2020)

 


 

SARS-CoV-2 antibodies from GeneTex 

 

Art. number Product description

GTX-GTX635654

SARS-CoV-2 Spike S1 antibody [HL6]

GTX-GTX632604

SARS-CoV-2 Spike S2 antibody [1A9]

GTX-GTX635654

SARS-CoV-2 Spike RBD antibody [HL1004]

GTX-GTX635679

SARS-CoV-2 nucleocapsid antibody [HL344]

GTX-GTX632269

SARS-CoV / SARS-CoV-2 nucleocapsid antibody [6H3]

GTX-GTX135467

SARS-CoV-2 RdRp (nsp12) polyclonal antibody

GTX-GTX632696

SARS-CoV / SARS-CoV-2 NSP8 antibody [5A10]

GTX-GTX632602

SARS-CoV / SARS-CoV-2 ORF7a antibody [3C9]

>> Additional COVID-19 antibodies from GeneTex

 


 

Monoclonal SARS-CoV-2 antibodies from BioServ UK

Art. number

Product description

BIS-BSV-N-01-*

Elite Anti-SARS-CoV-2 Nucleocapsid Protein Mab

BIS-BSV-RBD-01-*

Elite Anti-SARS-CoV-2 Spike (S1-RBD) Mab

BIS-BSV-S1-01-*

Elite Anti-SARS-CoV-2 Spike (S1) Mab

BIS-BSV-S2-01-*

Elite Anti-SARS-CoV-2 Spike (S2) Mab

 


 

CR3022 Variants from Absolute Antibody

 

The anti-SARS clone CR3022 was first described in 2006. In early 2020,  Tian et al. showed that the clone has a high affinity for SARS-CoV-2 (2019-nCoV). Scientists around the world are investigating this antibody as a candidate for the development of mono- and combination therapies.

Absolute Antibodies offers several engineered formats of the CR3022 clone that open up new experimental possibilities for in vitro and in vivo use, including IgG1, IgG2, IgG3, IgA, IgM, as well as human and murine Fab and Fab2 formats with His tags. Further variants are in work.

 

>> CR3022 recombiant Anti-SARS antibodies from Absolute Antibody

 


 

Further products and information:

 

>> all SARS-CoV-2 antibodies in the BIOZOL web shop

>> Webinar: COVID-19 - Bioactivity Evaluation of Neutralizing Antibodies In Vitro

>> Journal Club: Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

>> Journal Club: Neuropathology of patients with COVID-19 in Germany

18.11.2020

Other News

vectashield

Shine bright

Vectashield Antifade Mounting Media

brexit

Brexit

Deliveries from UK

genetex-sars-cov-2

SARS-CoV-2 research

GeneTex' comprehensive portfolio of antibodies

Secondary-Antibody-Selection-Guide

Secondary Antibodies

Online Selection Guide

covid-19-mutanten

COVID-19 Mutant Prot...

Recombinant SARS-CoV-2 Spike Protein Variants